Brian Finan, Ph.D. - Publications

Affiliations: 
2011 Biochemistry Indiana University, Bloomington, Bloomington, IN, United States 
Area:
endocrinology, specifically diabetes

49 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Yang B, Gelfanov VM, Perez-Tilve D, DuBois B, Rohlfs R, Levy J, Douros JD, Finan B, Mayer JP, DiMarchi RD. Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. Journal of Medicinal Chemistry. PMID 33821647 DOI: 10.1021/acs.jmedchem.0c02069  0.8
2021 Klein AB, Nicolaisen TS, Ørtenblad N, Gejl KD, Jensen R, Fritzen AM, Larsen EL, Karstoft K, Poulsen HE, Morville T, Sahl RE, Helge JW, Lund J, Falk S, Lyngbæk M, ... ... Finan B, et al. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise. Nature Communications. 12: 1041. PMID 33589633 DOI: 10.1038/s41467-021-21309-x  0.4
2021 Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, ... ... Finan B, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metabolism. PMID 33571454 DOI: 10.1016/j.cmet.2021.01.015  0.8
2020 Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Böttcher A, Sánchez-Garrido MA, Tarquis-Medina M, Kleinert M, Fischer K, Jall S, Harger A, Bader E, Roscioni S, Ussar S, Feuchtinger A, ... ... Finan B, et al. Author Correction: Targeted pharmacological therapy restores β-cell function for diabetes remission. Nature Metabolism. 2: 380. PMID 33820985 DOI: 10.1038/s42255-020-0201-1  0.8
2020 Zizzari P, He R, Falk S, Bellocchio L, Allard C, Clark S, Lesté-Lasserre T, Marsicano G, Clemmensen C, Perez-Tilve D, Finan B, Cota D, Quarta C. CB1 and GLP-1 Receptors Cross-Talk Provides New Therapies for Obesity. Diabetes. PMID 33144338 DOI: 10.2337/db20-0162  0.8
2020 Pan J, Parlee SD, Brunel FM, Li P, Lu W, Perez-Tilve D, Liu F, Finan B, Kharitonenkov A, DiMarchi RD. Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21. Acs Pharmacology & Translational Science. 3: 978-986. PMID 33073195 DOI: 10.1021/acsptsci.0c00100  0.8
2020 Sachs S, Niu L, Geyer P, Jall S, Kleinert M, Feuchtinger A, Stemmer K, Brielmeier M, Finan B, DiMarchi RD, Tschöp MH, Albrechtsen NW, Mann M, Müller TD, Hofmann SM. Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice. Diabetes, Obesity & Metabolism. PMID 33001570 DOI: 10.1111/dom.14215  0.8
2020 Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Böttcher A, Sánchez-Garrido MA, Tarquis-Medina M, Kleinert M, Fischer K, Jall S, Harger A, Bader E, Roscioni S, Ussar S, Feuchtinger A, ... ... Finan B, et al. Targeted pharmacological therapy restores β-cell function for diabetes remission. Nature Metabolism. 2: 192-209. PMID 32694693 DOI: 10.1038/s42255-020-0171-3  0.8
2020 Stemmer K, Finan B, DiMarchi RD, Tschöp MH, Müller TD. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews. PMID 32485206 DOI: 10.1016/J.Addr.2020.05.008  0.8
2019 Knerr PJ, Mowery SA, Finan B, Perez-Tilve D, Tschöp MH, DiMarchi RD. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. Peptides. 170225. PMID 31786282 DOI: 10.1016/J.Peptides.2019.170225  0.8
2019 Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 30: 72-130. PMID 31767182 DOI: 10.1016/J.Molmet.2019.09.010  0.8
2019 Zaykov AN, Gelfanov VM, Perez-Tilve D, Finan B, DiMarchi RD. Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice. Peptides. 120: 170116. PMID 31348991 DOI: 10.1016/J.Peptides.2019.170116  0.8
2019 Brunel FM, Mayer JP, Gelfanov VM, Zaykov AN, Finan B, Perez-Tilve D, DiMarchi RD. A disulfide-scan of insulin by [3+1] methodology exhibits site-specific influence on bioactivity. Acs Chemical Biology. PMID 31343157 DOI: 10.1021/Acschembio.9B00420  0.8
2019 He R, Finan B, Mayer JP, DiMarchi RD. Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules (Basel, Switzerland). 24. PMID 31091786 DOI: 10.3390/Molecules24101855  0.8
2019 Décarie-Spain L, Fisette A, Zhu Z, Yang B, DiMarchi RD, Tschöp MH, Finan B, Fulton S, Clemmensen C. GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. Neuropharmacology. PMID 30946847 DOI: 10.1016/J.Neuropharm.2019.03.035  0.8
2019 Ratner C, He Z, Grunddal KV, Skov LJ, Hartmann B, Zhang F, Feuchtinger A, Bjerregaard A, Christoffersen C, Tschöp MH, Finan B, DiMarchi RD, Leinninger GM, Williams KW, Clemmensen C, et al. Long Acting Neurotensin Synergizes with Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway. Diabetes. PMID 30936142 DOI: 10.2337/Db18-1009  0.8
2018 Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD, Perez-Tilve D. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Molecular Metabolism. PMID 30578168 DOI: 10.1016/J.Molmet.2018.12.001  0.8
2018 Clemmensen C, Finan B, Müller TD, DiMarchi RD, Tschöp MH, Hofmann SM. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nature Reviews. Endocrinology. PMID 30446744 DOI: 10.1038/S41574-018-0118-X  0.8
2018 Khajavi N, Finan B, Kluth O, Müller TD, Mergler S, Schulz A, Kleinau G, Scheerer P, Schürmann A, Gudermann T, Tschöp MH, Krude H, DiMarchi RD, Biebermann H. An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation. Cellular Signalling. 51: 13-22. PMID 30055232 DOI: 10.1016/J.Cellsig.2018.07.006  0.8
2018 Kim T, Nason S, Holleman C, Pepin M, Wilson L, Berryhill TF, Wende AR, Steele C, Young ME, Barnes S, Drucker DJ, Finan B, DiMarchi R, Perez-Tilve D, Tschoep M, et al. Glucagon-receptor Signaling Regulates Energy Metabolism Via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21. Diabetes. PMID 29925501 DOI: 10.2337/Db17-1502  0.8
2018 Capozzi ME, DiMarchi RD, Tschöp MH, Finan B, Campbell JE. Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes. Endocrine Reviews. PMID 29905825 DOI: 10.1210/Er.2018-00117  0.8
2018 Agrawal A, Parlee S, Perez-Tilve D, Li P, Pan J, Mroz PA, Kruse Hansen AM, Andersen B, Finan B, Kharitonenkov A, DiMarchi RD. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Molecular Metabolism. PMID 29789271 DOI: 10.1016/J.Molmet.2018.05.003  0.8
2017 Knerr PJ, Finan B, Gelfanov V, Perez-Tilve D, Tschöp MH, DiMarchi RD. Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorganic & Medicinal Chemistry. PMID 29153547 DOI: 10.1016/J.Bmc.2017.10.047  0.8
2017 Quarta C, Clemmensen C, Zhu Z, Yang B, Joseph SS, Lutter D, Yi CX, Graf E, García-Cáceres C, Legutko B, Fischer K, Brommage R, Zizzari P, Franklin BS, Krueger M, ... ... Finan B, et al. Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity. Cell Metabolism. PMID 28943448 DOI: 10.1016/J.Cmet.2017.08.023  0.8
2017 Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, Tschöp MH, Müller TD, Hofmann SM. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Molecular Metabolism. 6: 440-446. PMID 28462078 DOI: 10.1016/J.Molmet.2017.02.002  0.8
2016 Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Liu P, Tuckermann J, et al. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell. PMID 27720451 DOI: 10.1016/J.Cell.2016.09.014  0.8
2016 Sánchez-Garrido MA, Habegger KM, Clemmensen C, Holleman C, Müller TD, Perez-Tilve D, Li P, Agrawal AS, Finan B, Drucker DJ, Tschöp MH, DiMarchi RD, Kharitonenkov A. Fibroblast activation protein (FAP) as a novel metabolic target. Molecular Metabolism. 5: 1015-24. PMID 27689014 DOI: 10.1016/J.Molmet.2016.07.003  0.8
2016 Vogel H, Wolf S, Rabasa C, Rodriguez-Pacheco F, Babaei CS, Stöber F, Goldschmidt J, DiMarchi RD, Finan B, Tschöp MH, Dickson SL, Schürmann A, Skibicka KP. GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight. Neuropharmacology. PMID 27496691 DOI: 10.1016/J.Neuropharm.2016.07.039  0.4
2016 Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism. 24: 51-62. PMID 27411008 DOI: 10.1016/J.Cmet.2016.06.021  0.8
2016 Finan B, Müller TD, Clemmensen C, Perez-Tilve D, Tschöp MH. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends in Molecular Medicine. PMID 27038883 DOI: 10.1016/J.Molmed.2016.03.005  0.4
2016 Kabra DG, Pfuhlmann K, García-Cáceres C, Schriever SC, Casquero García V, Kebede AF, Fuente-Martin E, Trivedi C, Heppner K, Uhlenhaut NH, Legutko B, Kabra UD, Gao Y, Yi CX, Quarta C, ... ... Finan B, et al. Hypothalamic leptin action is mediated by histone deacetylase 5. Nature Communications. 7: 10782. PMID 26923837 DOI: 10.1038/Ncomms10782  0.4
2015 Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Molecular and Cellular Endocrinology. PMID 26151488 DOI: 10.1016/J.Mce.2015.07.003  0.4
2015 Clemmensen C, Müller TD, Finan B, Tschöp MH, DiMarchi R. Current and Emerging Treatment Options in Diabetes Care. Handbook of Experimental Pharmacology. PMID 25903416 DOI: 10.1007/164_2015_7  0.4
2015 Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, Heine D, Grassl N, Meyer CW, Henderson B, Hofmann SM, Tschöp MH, Van der Ploeg LH, Müller TD. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. Embo Molecular Medicine. 7: 288-98. PMID 25652173 DOI: 10.15252/Emmm.201404508  0.4
2015 Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschöp MH, Schürmann A. GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia. 58: 604-14. PMID 25527001 DOI: 10.1007/S00125-014-3478-3  0.8
2015 Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 21: 27-36. PMID 25485909 DOI: 10.1038/Nm.3761  0.4
2015 Müller TD, Clemmensen C, Finan B, Dimarchi RD, Tschöp MH. Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases Leptin: Regulation and Clinical Applications. 267-279. DOI: 10.1007/978-3-319-09915-6_21  0.4
2014 Morselli E, Fuente-Martin E, Finan B, Kim M, Frank A, Garcia-Caceres C, Navas CR, Gordillo R, Neinast M, Kalainayakan SP, Li DL, Gao Y, Yi CX, Hahner L, Palmer BF, et al. Hypothalamic PGC-1α protects against high-fat diet exposure by regulating ERα. Cell Reports. 9: 633-45. PMID 25373903 DOI: 10.1016/J.Celrep.2014.09.025  0.4
2014 Cansell C, Castel J, Denis RG, Rouch C, Delbes AS, Martinez S, Mestivier D, Finan B, Maldonado-Aviles JG, Rijnsburger M, Tschöp MH, DiLeone RJ, Eckel RH, la Fleur SE, Magnan C, et al. Dietary triglycerides act on mesolimbic structures to regulate the rewarding and motivational aspects of feeding. Molecular Psychiatry. 19: 1095-105. PMID 24732670 DOI: 10.1038/Mp.2014.31  0.4
2014 Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Küchler D, Sehrer L, Ograjsek T, Hofmann SM, Schriever SC, Pfluger PT, Pinkstaff J, Tschöp MH, Dimarchi R, Müller TD. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes. 63: 1422-7. PMID 24379349 DOI: 10.2337/Db13-1609  0.4
2014 Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschöp MH, Schürmann A. GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice Diabetologia. 58: 604-614. DOI: 10.1007/s00125-014-3478-3  0.4
2013 Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Science Translational Medicine. 5. PMID 24174327 DOI: 10.1126/Scitranslmed.3007218  0.4
2013 Fuente-Martin E, Garcia-Caceres C, Morselli E, Clegg DJ, Chowen JA, Finan B, Brinton RD, Tschöp MH. Estrogen, astrocytes and the neuroendocrine control of metabolism. Reviews in Endocrine & Metabolic Disorders. 14: 331-8. PMID 24009071 DOI: 10.1007/S11154-013-9263-7  0.4
2013 Müller TD, Müller A, Yi CX, Habegger KM, Meyer CW, Gaylinn BD, Finan B, Heppner K, Trivedi C, Bielohuby M, Abplanalp W, Meyer F, Piechowski CL, Pratzka J, Stemmer K, et al. The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. Nature Communications. 4: 1968. PMID 23744028 DOI: 10.1038/Ncomms2968  0.4
2013 Müller A, Kleinau G, Piechowski CL, Müller TD, Finan B, Pratzka J, Grüters A, Krude H, Tschöp M, Biebermann H. G-protein coupled receptor 83 (GPR83) signaling determined by constitutive and zinc(II)-induced activity. Plos One. 8: e53347. PMID 23335960 DOI: 10.1371/Journal.Pone.0053347  0.4
2013 Müller TD, Lee SJ, Jastroch M, Kabra D, Stemmer K, Aichler M, Abplanalp B, Ananthakrishnan G, Bhardwaj N, Collins S, Divanovic S, Endele M, Finan B, Gao Y, Habegger KM, et al. p62 links β-adrenergic input to mitochondrial function and thermogenesis. The Journal of Clinical Investigation. 123: 469-78. PMID 23257354 DOI: 10.1172/Jci64209  0.4
2013 Müller T, Müller A, Habegger K, Yi C, Meyer C, Gaylinn B, Finan B, Heppner K, Trivedi C, Bielohuby M, Abplanalp W, Meyer F, Piechowski C, Pratzka J, Stemmer K, et al. The orphan receptor GPR83 regulates systemic energy metabolism via ghrelin-dependent and -independent mechanisms Experimental and Clinical Endocrinology & Diabetes. 121. DOI: 10.1055/S-0033-1336629  0.8
2012 Finan B, Yang B, Ottaway N, Stemmer K, Müller TD, Yi CX, Habegger K, Schriever SC, García-Cáceres C, Kabra DG, Hembree J, Holland J, Raver C, Seeley RJ, Hans W, et al. Targeted estrogen delivery reverses the metabolic syndrome. Nature Medicine. 18: 1847-56. PMID 23142820 DOI: 10.1038/Nm.3009  0.4
2012 Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT, Tschöp MH. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiological Reviews. 92: 1479-514. PMID 22811431 DOI: 10.1152/Physrev.00022.2011  0.4
Show low-probability matches.